Granzyme B in Autoimmune Skin Disease
Biomolecules · 18.02.2023 · 13 (2) · 388
DOI: 10.3390/biom13020388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 18.02.2023. Verfasst von Anna Gleave und 1 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Professional Firefighters' Burn and Wound Healing Laboratory, International Collaboration On Repair Discoveries (ICORD) Centre, Vanc…. Hauptthemen laut MEDLINE: Alopecia Areata, Pemphigoid, Bullous, Vitiligo, Autoimmune Diseases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Michael Smith Foundation for Health Research, Cancer Research Society.
Abstract (Originalsprache)
Autoimmune diseases often present with cutaneous symptoms that contribute to dysfunction, disfigurement, and in many cases, reduced quality-of-life. Unfortunately, treatment options for many autoimmune skin diseases are limited. Local and systemic corticosteroids remain the current standard-of-care but are associated with significant adverse effects. Hence, there is an unmet need for novel therapies that block molecular drivers of disease in a local and/or targeted manner. Granzyme B (GzmB) is a serine protease with known cytotoxic activity and emerging extracellular functions, including the cleavage of cell–cell junctions, basement membranes, cell receptors, and other structural proteins. While minimal to absent in healthy skin, GzmB is markedly elevated in alopecia areata, interface dermatitis, pemphigoid disease, psoriasis, systemic sclerosis, and vitiligo. This review will discuss the role of GzmB in immunity, blistering, apoptosis, and barrier dysfunction in the context of autoimmune skin disease. GzmB plays a causal role in the development of pemphigoid disease and carries diagnostic and prognostic significance in cutaneous lupus erythematosus, vitiligo, and alopecia areata. Taken together, these data support GzmB as a promising therapeutic target for autoimmune skin diseases impacted by impaired barrier function, inflammation, and/or blistering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Columbia Professional Firefighters' Burn and Wound Healing Laboratory, International Collaboration On Repair Discoveries (ICORD) Centre, Vancouver Coastal Health Research Institute, University of British Columbi…
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.
ORCID-Profile: Anna Gleave, David J Granville
Förderung
- CIHR
- Michael Smith Foundation for Health Research
- Cancer Research Society
- Eczema Society of Canada
- Mitacs
- Praxis Spinal Cord Institute
- LEO Foundation
- Canadian Institutes of Health Research
Zitieren
APA
Gleave, A., & Granville, D. J. (2023). Granzyme B in Autoimmune Skin Disease. Biomolecules, 13(2), 388. https://doi.org/10.3390/biom13020388
Vancouver
Gleave A, Granville DJ. Granzyme B in Autoimmune Skin Disease. Biomolecules. 2023;13(2):388. doi:10.3390/biom13020388
BibTeX
@article{Gleave2023,
author = {Gleave, Anna and Granville, David J},
title = {Granzyme B in Autoimmune Skin Disease},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {2},
pages = {388},
doi = {10.3390/biom13020388}
}
EUVIMED